(RTTNews) - Ipsen (IPSEY), Friday announced that Japan's Ministry of Health, Labour and Welfare has approved Bylvay also known as odevixibat for the treatment of pruritus associated with progressive ...

- FDA approval based on MARCH Phase 3 study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum ...

Preliminary trial findings suggest transdermal cannabis may help ease pruritus-related itching in patients undergoing hemodialysis. Cannabis cream relieved itching symptoms over the short-term in a ...

An Ipsen drug developed to treat the severe itching that accompanies certain liver disorders is now FDA approved for treating this complication in patients with Alagille syndrome. It’s the second ...

HSK21542, a selective agonist of kappa opioid receptors, significantly reduced itch intensity and quality of life over 12 weeks in patients receiving hemodialysis. HSK21542, a peripherally restricted ...

Please provide your email address to receive an email when new articles are posted on . In this video, Marlyn Mayo, MD, of the University of Texas Southwestern Medical Center, discusses data that shed ...

(RTTNews) - Ipsen SA (IPSEY) and Medison Pharma on Monday said Health Canada Approved Bylvay for the treatment of pruritus or severe itching in patients aged six months or older with Progressive ...

Please provide your email address to receive an email when new articles are posted on . Overall, 49% of patients on dialysis reported moderate itch, 30% had severe itch and 22% had mild itch. In ...